000			01495 a2200421 4500
005			20250515105605.0
264		0	_c20090115
008			200901s 0 0 eng d
022			_a0302-2838
024	7		_a10.1016/j.eururo.2008.01.021 _2doi
040			_aNLM _beng _cNLM
100	1		_aEfstathiou, Jason A
245	0	0	_aCardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. _h[electronic resource]
260			_bEuropean urology _cOct 2008
300			_a816-23 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aCardiovascular Diseases _xmortality
650	0	4	_aFlutamide _xadverse effects
650	0	4	_aGoserelin _xadverse effects
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultivariate Analysis
650	0	4	_aProstatic Neoplasms _xdrug therapy
650	0	4	_aTime Factors
700	1		_aBae, Kyounghwa
700	1		_aShipley, William U
700	1		_aHanks, Gerald E
700	1		_aPilepich, Miljenko V
700	1		_aSandler, Howard M
700	1		_aSmith, Matthew R
773	0		_tEuropean urology _gvol. 54 _gno. 4 _gp. 816-23
856	4	0	_uhttps://doi.org/10.1016/j.eururo.2008.01.021 _zAvailable from publisher's website
999			_c17749659 _d17749659